212pb-ng001
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 6, 2023 (NCT05725070)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIRadiopharmaceutical
FOLH1 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 212-lead
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05725070 | Early Phase 1 (Phase 1) | Mar 6, 2023 | ARTBIO Inc., University of Oslo |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ARTBIO Inc. | For profit | 1 | 1 | 1 | 2023 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1